瑞卢戈利

Tier C — Watch / trade

Relugolix · all drugs expiring in 2031 →

武田药品工业株式会社

Originator

2019

First approval

2031

Expiry (public)

$0.3B ▲

Peak sales

化学药

Type

Targets：GnRHR

Brand：ORGOVYX、Relumina

Indications (approved)：前列腺癌、平滑肌瘤

Regional status

批准上市

2020-12-18

批准上市

2022-04-29

China

临床三期

2017-04-18

Japan

批准上市

2019-01-08

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 9 · Total yield /

Code	CAS No.	Intermediate
RELU-001	174072-89-0 Available	ethyl 2-amino-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate
RELU-002	308831-93-8 Available	ethyl 2-((ethoxycarbonyl)amino)-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate
RELU-003	697-73-4 Available	2-(chloromethyl)-1,3-difluorobenzene
RELU-004	308831-94-9 Available	ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate
RELU-005	308831-95-0 Available	ethyl 4-(bromomethyl)-2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-5-(4-nitrophenyl)thiophene-3-carboxylate
RELU-006	308832-01-1 Available	ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-(((2-methoxyethyl)(methyl)amino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylate
RELU-007	577780-07-5 Available	ethyl 5-(4-aminophenyl)-2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-(((2-methoxyethyl)(methyl)amino)methyl)thiophene-3-carboxylate
RELU-008	737789-92-3 Available	ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-(((2-methoxyethyl)(methyl)amino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylate
RELU-009	737789-93-4 Available	2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-(((2-methoxyethyl)(methyl)amino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylic acid
RELU-010	5469-69-2 Available	6-chloropyridazin-3-amine
RELU-011	737789-61-6 Available	1-(4-(1-(2,6-difluorobenzyl)-5-(((2-methoxyethyl)(methyl)amino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea
RELU-012	50893-53-3 Available	1-chloroethyl carbonochloridate

Frequently asked questions

What are the approved indications of Relugolix?

Approved indications include: 前列腺癌, 平滑肌瘤.

When does the Relugolix patent expire?

Based on public sources, the Relugolix patent expires in 2031.

How many synthesis routes are recorded for Relugolix?

1 synthesis routes are recorded; the shortest is 9 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Relugolix intermediates?

12 intermediate CAS of Relugolix are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Relugolix intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-24